News
CMVLF
4.500
NaN%
--
Starbucks initiated, Expedia downgraded: Wall Street’s top analyst calls
TipRanks · 09/16 13:45
Cellectis downgraded to Underweight from Overweight at Barclays
TipRanks · 09/16 09:00
Ulta Beauty, Etsy upgraded: Wall Street’s top analyst calls
TipRanks · 09/15 13:41
Cellectis price target lowered to $8 from $10 at Baird
TipRanks · 09/15 11:00
Cellectis price target lowered to $3 from $4 at Wells Fargo
TipRanks · 09/15 10:25
Cellectis downgraded to Market Perform from Outperform at Citizens
TipRanks · 09/15 09:05
Cellectis pivots to in vivo gene editing and exits key CAR-T programs
TipRanks · 09/14 07:15
Cellectis Plans September 14 Business Update Webcast for Global Investors
TipRanks · 09/11 21:03
Barclays Sticks to Their Buy Rating for Cellectis SA (CLLS)
TipRanks · 08/07 08:36
Cellectis Advances Allogeneic CAR-T Pipeline as Cash Runway Extends Into Late 2027
TipRanks · 08/06 21:55
Cellectis Updates Share Capital and Voting Rights as of July 31, 2026
TipRanks · 08/05 21:34
Cellectis Sets August 6 Date to Release Q2 2026 Results
TipRanks · 07/30 21:31
Citizens biotech analyst holds an analyst/industry conference call
TipRanks · 07/06 18:35
Citizens biotech analysts hold an analyst/industry conference call
TipRanks · 07/02 19:25
Cellectis wins FDA RMAT status for leukemia CAR-T candidate lasme-cel; shares rise
Seeking Alpha · 06/10 04:12
Cellectis granted RMAT designation for lasmecabtagene timgedleucel from FDA
TipRanks · 06/09 20:40
Cellectis initiated with an Overweight at Barclays
TipRanks · 05/28 09:25
Cellectis SA (CLLS) Receives a Buy from Barclays
TipRanks · 05/28 09:08
Cellectis to present clinical data on lasme-cel, eti-cel at EHA Congress
TipRanks · 05/12 19:21
Cellectis reports Q1 adjusted EPS (16c) vs. (17c) last year
TipRanks · 05/11 23:35
More
Webull provides a variety of real-time CMVLF stock news. You can receive the latest news about Cellectis through multiple platforms. This information may help you make smarter investment decisions.
About CMVLF
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.